The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

October 27, 2017 • By Nate Raymond

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

You Might Also Like
  • Prosecutors Identify Insys Founder as Unindicted Co-conspirator in Opioid Case
  • Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe
  • Former Insys CEO Pleads Guilty to Opioid Kickback Scheme
Also By This Author
  • Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged with engaging in conspiracies to commit racketeering, mail fraud and wire fraud in an indictment filed in federal court in Boston.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

He was arrested in Arizona, where Insys is based, and added as a defendant in a previously filed case against six former Insys executives and managers, including former Chief Executive Michael Babich, prosecutors said.

Brian Kelly, Kapoor’s lawyer, in a statement said: “My client is innocent and he intends to fight these charges vigorously.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Insys, which has been in settlement talks with the U.S. Justice Department in connection with the probe, declined to comment.

The charges marked a major escalation of the ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains fentanyl, a highly addictive synthetic opioid. They came as U.S. President Donald Trump on Thursday declared the U.S. opioid crisis a public health crisis.

Acting U.S. Attorney William Weinreb said the charges reflected authorities’ commitment to combat the opioid abuse epidemic. According to the U.S. Centers for Disease Control and Prevention, opioids were involved in over 33,000 deaths in 2015.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We must hold the industry and its leadership accountable – just as we would the cartels or a street-level drug dealer,” Weinreb said in a statement.

Kapoor, who founded Insys in 2002 and remains a board member, stepped down in January as the company’s chairman and chief executive, a role he took on in November 2015.

He is currently the chairman of drugmaker Akorn Inc, which Fresenius SE & Co KGaA has agreed to buy, and president of investment firm EJ Financial Enterprises Inc.

Prosecutors said that after launching Subsys in 2012, Kapoor, Babich and others devised a scheme to pay speaker fees and other bribes to medical practitioners to prescribe Subsys.

They also sought to defraud insurers into approving payment for Subsys when it was prescribed to patients who did not have cancer, the indictment said.

The other defendants include former Insys Vice Presidents Alec Burlakoff and Michael Gurry; ex-national sales director Richard Simon; and former regional sales directors Sunrise Lee and Joseph Rowan. They have pleaded not guilty.

 

Pages: 1 2 | Multi-Page

Filed Under: Legal Tagged With: billionaire Insys founder, Cancer, fentanyl-based cancer pain drug, Insys Therapeutics Inc, John Kapoor, national opioid addiction epidemic, opioid crisis, U.S. opioid bribe case

You Might Also Like:
  • Prosecutors Identify Insys Founder as Unindicted Co-conspirator in Opioid Case
  • Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe
  • Former Insys CEO Pleads Guilty to Opioid Kickback Scheme
  • Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)